AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JUN 3 - (NewsRx.com & NewsRx.net) -- Somatostatin receptor subtype 2 may represent a cell differentiation marker in tumors.
According to researchers writing in the journal Digestive and Liver Disease, "The presence of cellular somatostatin receptors, particularly of subtype 2, has been reported in a large number of human primary non-neuroendocrine tumors, such as breast and colon cancer."
M.C. Smith and colleagues continued, "Our aim was to evaluate whether subtype 2 expression may represent a prognostic factor in these tumors, and if the exact determination of its expression might help to identify patients eligible for a new treatment modality based on somatostatin analogues. Large groups of neuroblastomas as well as breast and colon cancers were studied for subtype 2 expression."
"In the two latter groups the expression of subtype 2 was evaluated both in tumor and in the corresponding normal tissue from the same patient, to correctly evaluate any modification of subtype 2 mRNA expression in cancer," the authors reported. "Subtype 2 mRNA expression was measured with accurate quantitative retro transcription-polymerase chain reaction procedures (first, by competitive polymerase chain reaction and then, by real-time assays).
"When possible, results of mRNA measurement were compared with in vitro (in situ hybridization ...
Source: HighBeam Research, Somatostatin receptor subtype 2 represents cell differentiation...